QUEBEC – JULY 11, 2006 - Advitech inc. (TSX-V: AVI) today announced, following the analysis by biostatisticians from JSS Medical Research on the data generated by the 2005 clinical study, statistically significant efficacy results and important clinical trends with regard to Dermylex™ in the treatment of mild to moderate psoriasis. When compared to the placebo group, the Dermylex™ treated group showed a reduction in psoriasis area and severity index (PASI), itching sensation and Body Surface Area (BSA).

1. PASI: An improvement in the PASI scores, while on the Dermylex™ treatment, that approached statistical significance after 56 days was observed while no change occurred in the placebo group. Moreover, almost 30% of the patients in the Dermylex™ treated group achieved a mean PASI improvement of 59% after 112 days.

2. Itching sensation: For the Dermylex™ treated group, intra-group absolute change in the itching sensation was statistically reduced after 112 days compared to day 1.

3. BSA: For the Dermylex™ treated group, the intra-group percent change was statistically significant between day 56 and day 1. In addition, the intergroup improvements at day 56 showed a major clinical trend in favour of the Dermylex™ treated group. Lastly, more than 25% of the Dermylex™ treated group showed a mean BSA improvement of 50% after 112 days.

“This additional data provides Advitech and its commercial partners with new clinical results confirming the efficacy of Dermylex in the treatment of the symptoms associated with mild-tomoderate psoriasis and makes the product well positioned for further development,” stated Dr Christina Juneau, Vice-President, Research and Development.

JOURNAL OF CUTANEOUS MEDICINE AND SURGERY TO PUBLISH DERMYLEX ™ OPEN STUDY
The Journal of Cutaneous Medicine and Surgery, a peer reviewed journal, will publish this month the open clinical study results performed in early 2004 with Dermylex™, while an article on the results of the 2005 double blind, placebo-controlled clinical study has received provisional acceptance pending the completion of satisfactory reviews by the assessment committee and should be published in the coming months.

About Advitech
Advitech is a life science and technology company specializing in the development of clinically tested bioactive ingredients for chronic immune-mediated inflammatory diseases (IMID), such as psoriasis and inflammatory bowel diseases. Advitech’s common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of common shares outstanding is 54,799,818.

About Dermylex™
Dermylex™ is Advitech’s orally administered product for mild to moderate plaque psoriasis made from a bioactive ingredient with proven clinical efficacy. On July 5, 2005, the Company reported positive results from its Phase II clinical trial for treating mild to moderate psoriasis. The 112-day, multi-center, double blind, placebo-controlled study, involving 84 patients, confirmed the efficacy and excellent safety profile of Dermylex™ for treating mild to moderate psoriasis. For more information please visit www.dermylex.ca

About JSS Medical Research
JSS Medical Research Inc. is an independent, fully integrated, contract research organization (CRO) offering a wide range of consulting and research services to pharmaceutical companies, hospitals, universities and government agencies.

-30-

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ significantly from those projected herein. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.